Differential roles of Src in transforming growth factor-β regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 797-805

  Ungefroren, Hendrik ^a,b   Sebens, Susanne ^a,c   Groth, Stephanie ^a,b   Gieseler, Frank ^b   Fändrich, Fred ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

p38 MAPK; Smad; Src; TGF

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE P60; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH DISORDER; GROWTH INHIBITION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PANCREATIC DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPORTER GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; CELL GROWTH PROCESSES; CELL MOVEMENT; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RNA, SMALL INTERFERING; SMAD PROTEINS; SRC-FAMILY KINASES; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 79952010499     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.897     Document Type: Article

References (41)

1. Summy JM and Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358, 2003. (Pubitemid 36791891)
2. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, Tarin D, Shattil SJ and Cheresh DA: An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15: 1163-1169, 2009.
3. Iliopoulos D, Hirsch HA and Struhl K: An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139: 693-706, 2009.
4. Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN, Pan ZK, Dong Z and Huang S: Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene 28: 3047-3057, 2009.
5. Flossmann-Kast BB, Jehle PM, Hoeflich A, Adler G and Lutz MP: Src stimulates insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res 58: 3551-3554, 1998. (Pubitemid 28376549)
6. Menke A, Philippi C, Vogelmann R, Seidel B, Lutz MP, Adler G and Wedlich D: Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 61: 3508-3517, 2001. (Pubitemid 32695048)
7. Trevino JG, Summy JM, Gray MJ, Nilsson MB, Lesslie DP, Baker CH and Gallick GE: Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res 65: 7214-7222, 2005. (Pubitemid 41161252)
8. Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, Barge A, Green T, Fennell M and Bruns CJ: Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10: 8028-8036, 2004. (Pubitemid 39587544)
9. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10: 2307-2318, 2004. (Pubitemid 38445688)
10. Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch KW and Bruns CJ: Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene 27: 7212-7222, 2008.
11. Moustakas A, Pardali K, Gaal A and Heldin CH: Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 82: 85-91, 2002. (Pubitemid 34468039)
12. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577-584, 2003. (Pubitemid 37280136)
13. Warshaw AL and Fernández del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
14. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI and Korc M: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856, 1993.
15. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H, Buchler MW and Adler G: Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243: 503-508, 1998. (Pubitemid 28414054)
16. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D and De Pinho RA: Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146, 2006. (Pubitemid 44790628)
17. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, Wright CV and Moses HL: Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20: 3147-3160, 2006. (Pubitemid 44790629)
18. Schniewind B, Groth S, Sebens Müerköster S, Sipos B, Schäfer H, Kalthoff H, Fändrich F and Ungefroren H: Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene 26: 4850-4862, 2007. (Pubitemid 47093169)
19. Ito H, Gardner-Thorpe, Zinner, MJ, Ashley SW and Whang EE: Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134: 221-226, 2003. (Pubitemid 37070342)
20. Galliher AJ and Schiemann WP: Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8: R42, 2006.
21. Bierie B and Moses HL: Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520, 2006.
22. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A and Arteaga CL: Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 69: 475-482, 2009.
23. Donnini S, Monti M, Castagnini C, Solito R, Botta M, Schenone S, Giachetti A and Ziche M: Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int J Cancer 120: 995-1004, 2007. (Pubitemid 46214298)
24. Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H and Maruta H: Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). Cancer Lett 245: 242-251, 2007. (Pubitemid 44959361)
25. Maeda M, Shintani Y, Wheelock MJ and Johnson KR: Src activation is not necessary for transforming growth factor (TGF)-β-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. J Biol Chem 281: 59-68, 2006. (Pubitemid 43671163)
26. Bain J, McLauchlan H, Elliott M and Cohen P: The specificities of protein kinase inhibitors: an update. Biochem J 371: 199-204, 2003. (Pubitemid 36458094)
27. Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H and Ungefroren H: Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem 277: 36118-36128, 2002.
28. Liu N, Furukawa T, Kobari M and Tsao MS: Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 153: 263-269, 1998. (Pubitemid 28317529)
29. Ouyang H, Mou Lj, Luk C, Liu N, Karaskova J, Squire J and Tsao MS: Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157: 1623-1631, 2000.
30. Groth S, Schulze M, Kalthoff H, Fändrich F and Ungefroren H: Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J Biol Chem 280: 33190-33199, 2005. (Pubitemid 41397114)
31. Geismann C, Morscheck M, Koch D, Bergmann F, Ungefroren H, Arlt A, Tsao MS, Bachem MG, Altevogt P, Sipos B, Fölsch UR, Schäfer H and Sebens Müerköster S: Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res 69: 4517-45426, 2009.
32. Voss M, Wolff B, Savitskaia N, Ungefroren H, Deppert W, Schmiegel W, Kalthoff H and Naumann M: TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol 14: 93-101, 1999.
33. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G and Gress TM: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228, 2001. (Pubitemid 32720992)
34. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G and Gress TM: TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204-211, 2001. (Pubitemid 32574276)
35. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ and Hill CS: SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74, 2002. (Pubitemid 34680517)
36. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K and Saito H: Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J 21: 6473-6482, 2002. (Pubitemid 35448425)
37. Dreissigacker U, Mueller MS, Unger M, Siegert P, Genze F, Gierschik P and Giehl K: Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal 18: 1156-1168, 2006. (Pubitemid 43674042)
38. Bakin AV, Rinehart C, Tomlinson AK and Arteaga CL: p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 115: 3193-3206, 2002
39. Galliher AJ and Schiemann WP: Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 67: 3752-3758, 2007. (Pubitemid 46762161)
40. Lee YH, Kayyali US, Sousa AM, Rajan T, Lechleider RJ and Day RM: Transforming growth factor-beta1 effects on endothelial monolayer permeability involve focal adhesion kinase/Src. Am J Respir Cell Mol Biol 37: 485-493, 2007. (Pubitemid 47502724)
41. Giehl K, Seidel B, Gierschik P, Adler G and Menke A: TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 19: 4531-4541, 2000.